- Home
- IBIO vs COCP Comparison
IBIO vs COCP Comparison
Compare IBIO & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- COCP
- Stock Information
- Founded
- IBIO 2008
- COCP 2006
- Country
- IBIO United States
- COCP United States
- Employees
- IBIO N/A
- COCP N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- COCP Health Care
- Exchange
- IBIO Nasdaq
- COCP Nasdaq
- Market Cap
- IBIO 16.4M
- COCP 15.4M
- IPO Year
- IBIO N/A
- COCP N/A
- Fundamental
- Price
- IBIO $0.87
- COCP $1.25
- Analyst Decision
- IBIO Strong Buy
- COCP Strong Buy
- Analyst Count
- IBIO 2
- COCP 1
- Target Price
- IBIO $5.50
- COCP $6.00
- AVG Volume (30 Days)
- IBIO 376.3K
- COCP 4.6M
- Earning Date
- IBIO 11-11-2025
- COCP 11-12-2025
- Dividend Yield
- IBIO N/A
- COCP N/A
- EPS Growth
- IBIO N/A
- COCP N/A
- EPS
- IBIO N/A
- COCP N/A
- Revenue
- IBIO $400,000.00
- COCP N/A
- Revenue This Year
- IBIO N/A
- COCP N/A
- Revenue Next Year
- IBIO N/A
- COCP N/A
- P/E Ratio
- IBIO N/A
- COCP N/A
- Revenue Growth
- IBIO 77.78
- COCP N/A
- 52 Week Low
- IBIO $0.56
- COCP $1.12
- 52 Week High
- IBIO $6.89
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- IBIO 60.39
- COCP 39.39
- Support Level
- IBIO $0.78
- COCP $1.19
- Resistance Level
- IBIO $0.86
- COCP $1.27
- Average True Range (ATR)
- IBIO 0.04
- COCP 0.08
- MACD
- IBIO 0.00
- COCP 0.01
- Stochastic Oscillator
- IBIO 95.55
- COCP 28.57
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).